Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and ABBV-838 with Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02951117Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Aug 2017
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of azintuxizumab vedotin in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose, Recommended Phase Two Dose and 1 more. Planned start Aug 2017; status: withdrawn.
02
Drugs
azintuxizumab vedotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02951117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951117.